Bottom line
IBB vs FBDIX: the short answer
IBB (iShares Biotechnology ETF) and FBDIX (Franklin Biotechnology Discovery Fund) are quite different portfolios: only about 34% of their top holdings (by weight) are shared.
But IBB is far broader, holding 254 positions to 126 for FBDIX, so beyond the top names it adds exposure FBDIX doesn't have.
IBB is cheaper at 0.44% vs 1.01% — a difference of $57 a year per $10,000 invested.
Over five years, FBDIX returned +5.0% a year vs +2.5% for IBB.
FBDIX has a front-end sales load of up to 5.5%; the other does not.
Updated Nov 19, 2026
IBB vs FBDIX side by side
| IBB | FBDIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Franklin Templeton |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 1.01% |
| Annual cost per $10k | $44 | $101 |
| 10-yr cost on $10k (prospectus) | $555 | $1,728 |
| Max front load | None | 5.5% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +28.0% | +43.9% |
| 5-yr return (annualized) | +2.5% | +5.0% |
| 10-yr return (annualized) | +4.4% | +6.4% |
| Best quarter | +26.8% | +29.5% |
| Worst quarter | −22.9% | −24.5% |
| Net assets (fund) | $5.9B | $1.2B |
| Number of holdings | 254 | 126 |
| Portfolio turnover | 27% | 38% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | FBDIX | Difference |
|---|---|---|---|
| 2025 | +28.0% | +52.3% | −24.3% |
| 2024 | −2.4% | +4.0% | −6.4% |
| 2023 | +3.6% | +18.4% | −14.8% |
| 2022 | −13.6% | −12.7% | −0.9% |
| 2021 | +1.0% | −17.7% | +18.7% |
| 2020 | +25.9% | +29.9% | −4.0% |
| 2019 | +24.8% | +34.8% | −10.1% |
| 2018 | −9.1% | −15.7% | +6.6% |
| 2017 | +21.2% | +18.8% | +2.4% |
| 2016 | −21.5% | −17.2% | −4.4% |
Source: Fund prospectus bar charts
Holdings overlap
7 of IBB's top 25 holdings also appear in FBDIX's top 25.
| Holding | IBB | FBDIX |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 3.54% |
| Gilead Sciences, Inc. | 7.52% | 3.86% |
| Amgen, Inc. | 7.50% | 4.39% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 3.77% |
| Argenx SE | 3.15% | 3.62% |
| Insmed, Inc. | 2.95% | 1.99% |
| Neurocrine Biosciences, Inc. | 1.34% | 1.82% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FBDIX top 10
- Jazz Pharmaceuticals plc — 5.66%
- Amgen, Inc. — 4.39%
- Gilead Sciences, Inc. — 3.86%
- Regeneron Pharmaceuticals, Inc. — 3.77%
- Argenx SE — 3.62%
- Vertex Pharmaceuticals, Inc. — 3.54%
- Franklin Institutional U.S. Government Money Market Fund — 3.18%
- Revolution Medicines, Inc. — 3.01%
- Guardant Health, Inc. — 2.76%
- Ascendis Pharma A/S — 2.56%
FAQ
What is the difference between IBB and FBDIX?
Which is cheaper, IBB or FBDIX?
Should I own both IBB and FBDIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.